Search research articles
Contact Us
Filters
Showing results (1-10 of 125) with videos related to
Page
of 13
Sort By:
Annals of Translational Medicine
|
April 30, 2019
Systemic therapy of elderly patients with advanced non-small cell lung cancer-individualized treatment is key
Robert Pirker
Clinical Advances in Hematology & Oncology : H&O
|
November 11, 2008
Cetuximab: potential role as first-line treatment for advanced non-small cell lung cancer
Robert Pirker
Nature Reviews. Clinical Oncology
|
September 28, 2011
Chemotherapy: advanced NSCLC--should we use doublets in elderly patients?
Robert Pirker
Expert Review of Anticancer Therapy
|
October 16, 2004
Darbepoetin alfa for the treatment of cancer-related anemia: an update
Robert Pirker
Current Opinion in Oncology
|
October 22, 2023
Immune checkpoint inhibitors as adjuvant therapy in patients with completely resected nonsmall cell lung cancer
Robert Pirker
The Lancet. Oncology
|
July 24, 2010
Bevacizumab in lung cancer: hurdles in clinical development
Robert Pirker
Memo
|
April 4, 2017
Milestones in the systemic treatment of lung cancer
Robert Pirker
Lung Cancer (Amsterdam, Netherlands)
|
November 24, 2004
Therapy of advanced non-small-cell lung cancer (take home message)
Robert Pirker
The Lancet. Oncology
|
November 25, 2017
EGFR monoclonal antibody biomarkers in advanced NSCLC: from translational research to clinical implementation
Robert Pirker
Expert Opinion on Drug Safety
|
December 22, 2006
Safety considerations for erythropoietin treatment in patients with cancer
Robert Pirker
Page
of 13
Search research articles
Search
Showing results (1-10 of 125) with videos related to
Sort By:
Page
of 13
Annals of Translational Medicine
|
April 30, 2019
Systemic therapy of elderly patients with advanced non-small cell lung cancer-individualized treatment is key
Robert Pirker
Clinical Advances in Hematology & Oncology : H&O
|
November 11, 2008
Cetuximab: potential role as first-line treatment for advanced non-small cell lung cancer
Robert Pirker
Nature Reviews. Clinical Oncology
|
September 28, 2011
Chemotherapy: advanced NSCLC--should we use doublets in elderly patients?
Robert Pirker
Expert Review of Anticancer Therapy
|
October 16, 2004
Darbepoetin alfa for the treatment of cancer-related anemia: an update
Robert Pirker
Current Opinion in Oncology
|
October 22, 2023
Immune checkpoint inhibitors as adjuvant therapy in patients with completely resected nonsmall cell lung cancer
Robert Pirker
The Lancet. Oncology
|
July 24, 2010
Bevacizumab in lung cancer: hurdles in clinical development
Robert Pirker
Memo
|
April 4, 2017
Milestones in the systemic treatment of lung cancer
Robert Pirker
Lung Cancer (Amsterdam, Netherlands)
|
November 24, 2004
Therapy of advanced non-small-cell lung cancer (take home message)
Robert Pirker
The Lancet. Oncology
|
November 25, 2017
EGFR monoclonal antibody biomarkers in advanced NSCLC: from translational research to clinical implementation
Robert Pirker
Expert Opinion on Drug Safety
|
December 22, 2006
Safety considerations for erythropoietin treatment in patients with cancer
Robert Pirker
Page
of 13